Evotec SE
EVT
Rank in Stocks
#10943
Evotec SE functions as a global collaborator, aiding the pharmaceutical and... Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
Share Price
$3.53
Last synced: 2026-11-09
Market Cap
$626.22M
Change (1 day)
-0.03%
Change (1 year)
-40.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Evotec SE (EVT)
Category
Healthcare
Operating Margin for Evotec SE (EVT)
Operating Margin as of November 2026 TTM: -17.68%
According to Evotec SE's latest financial reports, its current operating margin (TTM) is -17.68%. At the end of 2025 the company had an operating margin of -17.87%.
Operating Margin history for Evotec SE from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -17.68% | -1.06% |
| 2025 | -17.87% | -0.06% |
| 2024 | -17.88% | 194.08% |
| 2023 | -6.08% | -466.27% |
| 2022 | 1.66% | -62.44% |
| 2021 | 4.42% | -54.39% |
| 2020 | 9.69% | -30.88% |
| 2019 | 14.02% | -32.04% |
| 2018 | 20.63% | 41.79% |
| 2017 | 14.55% | -23.62% |
| 2016 | 19.05% | 108.88% |
| 2015 | 9.12% | -227.91% |
| 2014 | -7.13% | -71.30% |
| 2013 | -24.84% | 576.84% |
| 2012 | -3.67% | -156.46% |
| 2011 | 6.50% | 109.68% |
| 2010 | 3.10% | -103.13% |
| 2009 | -99.10% | -46.38% |
| 2008 | -184.81% | 4.58% |
| 2007 | -176.72% | 223.78% |
| 2006 | -54.58% | 6.15% |
| 2005 | -51.42% | -96.71% |
| 2004 | -1,562.82% | 68.44% |
| 2003 | -927.80% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -101.10% |
DE
|
|
| 19.68% | -101.11% |
DE
|
|
| 13.26% | -100.75% |
JP
|
|
| 17.08% | -100.97% |
CH
|
|
| 14.92% | -100.84% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Evotec SE's operating margin
What is Evotec SE's operating margin?
Evotec SE's operating margin is -17.68%, as of Nov 2026.
What was Evotec SE's operating margin in 2025?
In 2025, Evotec SE's operating margin was -17.87%, compared with -17.88% in 2024.
How has Evotec SE's operating margin changed since 2020?
From 2020 to 2025, Evotec SE's operating margin was highest in 2020 (9.69%) and lowest in 2024 (-17.88%).
How does Evotec SE's operating margin compare with similar companies?
Evotec SE's operating margin (-17.68%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.